-
Posted by
Two Blokes Jul 16 -
Filed in
Stock
-
4 views
Key acquisitions since 2022 increased Amgen's rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market's 10.35% CAGR up to 2037. A growing portfolio of biosimilar products will drive double-digit sales growth in the coming decade. The immense growth potential in both its rare disease and biosimilar portfolios is essential for Amgen to offset patent cliff headwinds.
